Aspergillus fumigatus is a saprophytic fungus that is ubiquitous in the environment and is commonly associated with allergic sensitization and severe asthma in humans. Although A. fumigatus is recognized by multiple microbial pattern-recognition receptors, we found that an A. fumigatus-derived glycosphingolipid, asperamide B, directly activates invariant natural killer T (iNKT) cells in vitro in a CD1d-restricted, MyD88-independent and dectin-1-independent fashion. Moreover, asperamide B, when loaded onto CD1d, directly stained, and was sufficient to activate, human and mouse iNKT cells. In vivo, asperamide B rapidly induced airway hyperreactivity, which is a cardinal feature of asthma, by activating pulmonary iNKT cells in an interleukin-33 (IL-33)-ST2-dependent fashion. Asperamide B is thus the first fungal glycolipid found to directly activate iNKT cells. These results extend the range of microorganisms that can be directly detected by iNKT cells to the kingdom of fungi and may explain how A. fumigatus can induce severe chronic respiratory diseases in humans.
Asthma is an inflammatory disease of the airways that affects 300 mil lion individuals worldwide. The inflammatory response in asthma is frequently driven by T helper type 2 (T H 2) cells and adaptive immu nity against environmental aeroallergens. Although allergenspecific T H 2 cells that mediate asthma recognize the protein components of allergens, most environmental allergens contain a complex mixture of lipids and carbohydrates that might function as adjuvants to enhance the process of sensitization. For example, house dust mite contains ligands of Tolllike receptor 4 (TLR4) 1 and dectin2 (also called CLEC6A) 2 , which activate innate immune cells, including dendritic cells, airway epithelial cells and macrophages, thereby enhancing the capacity of dust mites to stimulate adaptive T H 2 cell responses during the sensitization phase. However, other allergens such as fungi may use additional immunological mechanisms to enhance sensitization.
The saprophytic fungus A. fumigatus contains several clinically impor tant allergens and is highly associated with allergic asthma. A. fumigatus spores or conidia are recovered frequently from the environment, from within buildings and homes and in soil, resulting in daily respiratory exposure in most individuals 3, 4 . Although A. fumigatus can cause inva sive infection, primarily in immunocompromised hosts with defects in neutrophil function, in normal healthy individuals, A. fumigatus conidia are rapidly cleared by phagocytes after recognition through soluble and cellassociated microbial patternrecognition receptors, including TLR2, TLR4, surfactant proteins A and D, C3, dectin1 (also called CLEC7A) and DCSIGN (also called CD209) 5, 6 . However, in some individuals, allergic sensitization to A. fumigatus develops. In patients with asthma, allergic sensitization to A. fumigatus is associated with severe disease and reduced lung function 7, 8 . Indeed, a syndrome called severe asthma with fungal sensitization is often associated with A. fumigatus colonization of the lung 9 . Rarely, particularly in patients with severe asthma or with cystic fibrosis, a unique hypersensitivity response to A. fumigatus devel ops known as allergic bronchopulmonary aspergillosis, which is associ ated with very high concentrations of serum immunoglobulin E (IgE), eosinophilia, bronchiectasis, pulmonary infiltrates and chronic severe asthma symptoms 10 . However, the precise mechanisms for the innate immune recognition of A. fumigatus resulting in allergic sensitization and asthma are not fully known.
We therefore examined an innatelike pathway that might be activated by A. fumigatus involving iNKT cells. iNKT cells recognize glycolipid antigens presented by CD1d, rapidly produce large quantities of cytokines and are thought to have an important role in regulating the development of airway hyperreactivity (AHR), which is a cardinal feature of asthma 11 , although their role in human asthma is less clear 12 . iNKT cells express an invariant T cell receptor (iTCR), which is highly conserved evolutionarily and is thought to serve as a receptor for pathogenassociated molecular patterns. Until now, however, only a few microbes have been shown to express glycolipid antigens that can be directly recognized by the iTCR of iNKT cells. The high degree of conservation of the iNKT cell iTCR across many mammalian species suggests that other types of microorganisms, including fungi such as A. fumigatus, may also express glycolipids that can be recognized by the iTCR of iNKT cells.
RESULTS
An A. fumigatus extract rapidly induces AHR Intranasal treatment of wildtype BALB/c mice for 3 d with A. fumigatus extracts resulted in the development of severe AHR 24 h after the last dose ( Fig. 1a) . Our protocol was substantially shorter than previous protocols that have been used with A. fumigatus in which mice were repeatedly challenged with A. fumigatus over 2-4 weeks to induce potent T H 2 cell-mediated adaptive immunity [13] [14] [15] . In our studies, the severe AHR and airway inflammation in response to A. fumigatus extract occurred independently of adaptive immunity in mice deficient for MHC class II (homozygous null for H2 genes Ab1, Aa, Eb1, Eb2 and Ea called here H2.Ab1-Ea-null mice), which lack MHC class IIrestricted CD4 + T cells but have iNKT cells (Fig. 1b,c) . The induction of AHR by A. fumigatus extracts required IL4 and IL13, as it did not occur in Il4 −/− Il13 −/− mice ( Fig. 1d) . Although Il4 −/− Il13 −/− mice did not develop AHR, they did develop airway neutrophilia ( Fig. 1e) . mRNA levels for IL4 and IL13, but not interferonγ (IFNγ), were increased in the lungs after treatment with A. fumigatus, as shown by analysis of total lung RNA by quantitative PCR (qPCR) ( Fig. 1f) . These results suggest that the A. fumigatus extract contained glycolipids that activated iNKT cells.
The A. fumigatus extract did not induce AHR in iNKT celldeficient Cd1d1 −/− mice, whereas it caused severe AHR in wildtype mice ( Fig. 2a) . However, the recruitment of neutrophils to the air way was independent of CD1d ( Fig. 2b) . These data suggest that the A. fumigatus extract contains several immunomodulatory activities, such that AHR was CD1d, IL4 and IL13 dependent, whereas inflam mation was CD1d, IL4 and IL13 independent. The number of iNKT cells in the bronchoalveolar lavage (BAL) fluid and lungs increased after treatment with the A. fumigatus extract, as determined by flow cytometry, particularly in terms of the percentage of T cell receptor β chain (TCRβ) + cells and the absolute number of iNKT cells in the lungs ( Fig. 2c-f ). Moreover, Traj18 −/− (also known as Jα18 −/− ) mice, which, similarly to Cd1d1 −/− mice, lack iNKT cells, did not develop AHR ( Fig. 2g ), but this response was restored by adoptive transfer of CD1d tetramer-sorted wildtype iNKT cells ( Fig. 2g) . To control for the possibility that tetramer sorting could activate the transferred iNKT cells, we used unsorted wildtype splenocytes to reconstitute Traj18 −/− mice with iNKT cells, which also restored the AHR response to A. fumigatus (Supplementary Fig. 1 ). Together these experiments show that iNKT cells are required for the development of the acute AHR in response to the A. fumigatus extract.
Myd88 −/− mice treated with the A. fumigatus extract developed a reduced AHR response and significantly reduced neutrophil infil tration in their BAL fluid compared to wildtype mice ( Fig. 3a,b) . Moreover, Myd88 −/− mice did not respond when challenged intrana sally with only one dose (rather than three daily doses) of A. fumigatus extract and evaluated 24 h later, which is in contrast to wildtype mice, which developed severe AHR and airway inflammation ( Fig. 3c,d) . These findings suggest that the A. fumigatus extract contained fungal derived glycolipids that rapidly induced AHR, but that this response required signaling through TLR receptors or through the IL1 recep tor accessory protein (Il1Rap), which is a component of the IL1 and IL33 receptors. In contrast, the A. fumigatus-induced AHR response did not require Tolllike receptor adaptor molecule 1 (Ticam1), as Ticam1 Lps2/Lps2 mice, which have an early frameshift in the Ticam1 gene, fully responded to three intranasal doses of A. fumigatus, as did wildtype mice ( Fig. 3e,f) . In addition, the AHR response induced by the A. fumigatus extract was independent of dectin1, as pretreat ment with a dectin1-blocking antibody (500 µg per mouse) did not reduce AHR induced by the A. fumigatus extract ( Fig. 3g) , although the dectin1-blocking antibody reduced the influx of neutrophils into the BAL fluid by 50% ( Fig. 3h ) and reduced the in vivo induction of IL12 by the dectin1 ligand, laminarin (the β1,3 and β1,6 glucans from the seaweed Laminaria digitata) 16 (Fig. 3i ).
An A. fumigatus lipid directly activates iNKT cells We next purified total A. fumigatus lipids by Folch extration. We further fractionated and tested lipids for their capacity to cause cytokine production in primary iNKT cell lines until we isolated a Further characterization by singledimensional and multidimen sional NMR spectroscopy and mass spectrometry revealed spectral data that matched those of a previously reported glycosphingolipid called asperamide B (V.C., L.A.A., S. Deng, R.H.D., D.T.U. and P.B.S., unpublished data). Asperamide B has been isolated previously from culture extracts of Aspergillus niger, an endophytic fungus found in marine brown alga 17 . Notably, asperamide B (the structure of which is shown in Fig. 4a ) was present in significantly higher quantities in extracts from A. fumigatus than from A. niger ( Fig. 4b ; P < 0.001, Student's t test). Coculture of bone marrow-derived cells (BMDCs) and primary iNKT cells with purified asperamide B (pAspB) induced iNKT cells to produce IL4 and IFNγ in a dosedependent manner, with the concentrations of IL4 reaching statistical significance at the highest dose ( Fig. 4c and Supplementary Fig. 2a ). To confirm that aspera mide B and not an unknown contaminant induced iNKT cell cytokine secretion, we chemically synthesized asperamide B from component lipid and sugar moieties (V.C., L.A.A., S. Deng, R.H.D., D.T.U. and P.B.S., unpublished data). The synthesized asperamide B (sAspB) also induced IL4 and IFNγ production by iNKT cells in a dosedependent manner ( Fig. 4d and Supplementary Fig. 2b ). Activation of iNKT cells by asperamide B required CD1d, as cocul ture of iNKT cells with BMDCs from Cd1d1 −/− mice did not induce IL4 or IFNγ ( Fig. 4e and Supplementary Fig. 2c ). Asperamide B most likely directly activated the iNKT cells, as the induction of IL4 and IFNγ production by both the purified and synthetic versions of asperamide B was MyD88 and Ticam1 independent, which is similar to the response observed in a control culture with PBS57 (an αgalactosylceramide (αGalCer) analog) ( Fig. 4e) . Although previous studies showed that A. fumigatus indirectly activated iNKT cells by stimulating dectin1 on antigenpresenting cells (APCs) and inducing IL12 production 18 , blockade with a monoclonal antibody to dectin1 had no effect on iNKT cell activation by our A. fumigatus extract or by sAspB in cocultures ( Fig. 4f) , although the monoclonal antibody to dectin1 greatly reduced the induction of IL12 in BMDCs by the dectin1 ligand, laminarin ( Fig. 4g) . Furthermore, our A. fumigatus allergen extract induced only small amounts of IL12 in BMDCs ( Fig. 4h) , indicating that our A. fumigatus allergen extract, in con trast to other A. fumigatus extracts 18 , may contain less IL12-inducing pathogenassociated molecular pattern molecules (for example, βglucans). However, both the purified and synthetic versions of asperamide B also activated primary human iNKT cell lines to pro duce statistically significant amounts of IL4 and IL13 ( Fig. 4i,j) . npg These in vitro results suggest that A. fumigatus might drive respiratory disease in mice and humans in part through direct activation of iNKT cells by presentation of asperamide B on CD1d.
We loaded CD1d tetramers with the sAspB glycolipid and found that it stained splenic iNKT cells, which was similar to the staining that we observed with PBS57loaded tetramers (PBS57 is known to stain all iNKT cells) ( Fig. 5a) . The percentage of CD4 + cells and the Vβ distribution of the sAspB tetramer-positive and PBS57 tetramerpositive iNKT cells were also similar, as ~85% of both sAspB + and PBS57 + iNKT cells were CD4 + and ~50% stained positively with an antibody that recognizes Vβ8.1 + and Vβ8.2 + (Fig. 5b,c) . However, we noted small differences in the number of sAspB + and PBS57 + iNKT cells that stained with monoclonal antibodies to Vβ7 (13.8% for sAsp B and 11.5% for PBS57) or Vβ2 (9.8% of sAspB and 8.3% of PBS57). We confirmed the staining results with sAspB-loaded and PBS57 loaded CD1d tetramers, including the similar Vβ distributions of the stained cells, by staining primary iNKT cell lines ( Supplementary  Fig. 3a-c) . Incubation of iNKT cell lines simultaneously with both tetramers resulted in staining only with PBS57loaded tetramers (Supplementary Fig. 3d ), suggesting that both tetramers could bind the same iTCRs. Moreover, platebound sAspB-loaded, but not unloaded, CD1d monomers effectively activated primary iNKT cell lines (Fig. 5d) . The effect of the platebound CD1d monomers on the iNKT cell lines was amplified when we added a CD28activating antibody to these cultures (Fig. 5e) . These results together indicate that the sAspB and PBS57 CD1d tetramers stain similar populations of iNKT cells and that asperamide B can be directly recognized by the iTCR of iNKT cells.
Asperamide B induces AHR in vivo in wild-type mice A single dose of purified asperamide B administered to wildtype mice induced AHR within 24 h, although asperamide B was less potent than PBS57 (Fig. 5f) . Asperamide B also induced airway inflamma tion with a statistically significant increase in macrophage numbers and a small number of neutrophils that did not reach significance (Fig. 5g) . The numbers of lung iNKT cells producing IL4 alone or IL4 and IL13 were significantly increased, whereas the increase in the number of cells producing IL13 alone did not reach statistical significance (Fig. 5h) . We calculated these numbers from the total numbers of iNKT cells in the lung and the fraction of iNKT cells producing IL4 and IL13 (Supplementary Fig. 4a,b) . The AHR and airway inflammatory response to asperamide B required the presence of iNKT cells, as it did not occur in Cd1d1 −/− mice (Fig. 5i) , and also required IL4 and IL13, as it did not occur in Il4 −/− Il13 −/− mice ( Fig. 5j and Supplementary Fig. 4c) . These findings indicate that asperamide B is a major component of A. fumigatus that can induce the development of AHR and airway inflammation.
Similarly to the A. fumigatus extract, asperamide B did not induce AHR in Myd88 −/− mice after a single dose (Fig. 6a) . However, aspera mide B-induced AHR required signaling from the IL33 receptor, as Il1rl1 −/− mice (also known as ST2 −/− mice), which lack the receptor for IL33, did not develop AHR after challenge with aspera mide B (Fig. 6b) . Il1rl1 −/− mice showed normal populations of splenic iNKT cells compared to wildtype mice, ruling out a deficiency in iNKT cells as a cause for the absence of AHR in Il1rl1 −/− mice (Supplementary Fig. 5 ). We therefore hypothesized that asperamide Binduced AHR requires MyD88, as Il1Rap, a subunit of the IL33 npg receptor, requires MyD88 for signaling. Indeed, IL33 mRNA levels were greatly increased in the lungs of mice within 3 h of administra tion of asperamide B (Fig. 6c) . In addition, asperamide B induced IL33 production in several cell types, including alveolar and intersti tial macrophages (Fig. 6d) . The induction of IL33 in alveolar macro phages required iNKT TCR signaling, as cocultures of iNKT cells and alveolar macrophages had a significant increase in macrophage IL33 mRNA levels when stimulated with pAspB but not DMSO (Fig. 6e) .
These results indicate that A. fumigatus contains a glycolipid antigen that activates iNKT cells, which can induce alveolar macrophages and other APCs to produce IL33, which in turn is required for the development of AHR. In addition, these results together indicate that asperamide B directly activates iNKT cells and that the in vivo require ment for MyD88 in the AHR response to A. fumigatus reflects the need for ST2 signaling.
DISCUSSION
In these studies we identify a fungal glycosphingolipid antigen, asperamide B, that directly activates iNKT cells in a CD1drestricted, MyD88independent manner. To our knowledge, this is the first report of a fungal glycolipid antigen that directly activates both mouse and human iNKT cells, and therefore these studies extend the range of microorganisms that are known to directly activate iNKT cells. Moreover, we demonstrate that by activating iNKT cells, both purified and synthesized asperamide B rapidly induced AHR, a cardinal feature of asthma, in the absence of adaptive immunity and that asperamide B, when loaded into CD1d, could directly stain and activate iNKT cells. Because A. fumigatus is ubiquitous in the environment and is fre quently recovered from the respiratory tract, our observations are clinically relevant and may account for the potency of A. fumigatus in causing respiratory disease and severe asthma in humans.
The number of distinct microorganisms known to activate iNKT cells has grown rapidly over the past several years, but no previous study has found fungal glycolipid antigens that directly activate iNKT cells 19 . Initially, iNKT cells were thought to react primarily to Gramnegative bacteria that lack lipopolysaccharides (for example, Sphingomonas species) 20, 21 . However, subsequent studies demon strated that iNKT cells recognize lipids from several additional bac terial species, including Borrelia burgdorferi 22 , Helicobacter pylori 23 , Streptococcus pneumoniae and group B Streptococcus 24 . Our results showing that glycolipids from A. fumigatus directly activate iNKT cells extend the range of microorganisms that are directly detected by iNKT cells into another biological kingdom: fungi. Therefore, the ability of the semiinvariant TCR of iNKT to function as a pattern recognition receptor that recognizes both pathogenic bacteria and fungi may explain the extensive conservation of this iTCR in most mammalian species 25 .
Previous studies have suggested that although some microbial gly colipids can directly activate iNKT cells, the dominant pathway for iNKT cell activation during microbial infection involves the indirect pathway in which iNKT cells respond secondarily to IL12 produced by APCs activated by microbial pathogenassociated molecular patterns binding to patternrecognition receptors 26 . In particular, A. fumigatus expresses β1,3 glucans 18,27,28 , which trigger dectin1 and induce the production of IL12, which then secondarily activates iNKT cells 18 . However, A. fumigatus causes several different types of pathologies, including invasive tissue disease, hypersensitivity disease and asthma. Although the indirect, IL12-dependent pathway for npg iNKT cell activation may be important during invasive aspergillosis 29 , it may be less relevant for A. fumigatus hypersensitivity disease occur ring at mucosal surfaces 30 . In this mucosal response, asperamide B may directly activate iNKT cells, triggering the production of IL13 and IL33 independently of dectin1 and IL12. Thus, these distinct pathways may be differentially engaged depending on the setting npg (for example, in the airways compared to in the tissues), although it is possible that the βglucan and dectin1 and the asperamide B path ways may overlap and synergize in some conditions, such as chronic fungal exposure 31, 32 .
The A. fumigatus glycolipid identified in our studies, asperamide B, which could activate both mouse and human iNKT cells, stimulated mouse iNKT cells in vitro in a MyD88independent manner. In con trast, the in vivo induction of AHR by the A. fumigatus glycolipid required MyD88, presumably because the induction of AHR by asperamide B also required IL33 and its receptor, ST2. Signaling through ST2 requires MyD88, as the IL33 receptor heterodimeric complex includes both ST2 and Il1Rap, which recruits and utilizes the Toll and interleukin receptor (TIR)binding adaptor protein, MyD88. In the lungs, we propose that asperamide B activates iNKT cells, which then trigger APCs such as alveolar macrophages to produce IL33. A similar induction of IL33 in alveolar macrophages by iNKT cells was recently described with αgalactosylceramide and Sphingomonas glycolipids in the lungs 33 and in hepatocytes in the liver 34 . After being secreted in the lungs, IL33 can activate a subset of IL33-responsive iNKT cells 35 and type 2 innate lymphoid cells (ILC2 cells, also called nuocytes or natural helper cells [35] [36] [37] [38] [39] [40] ), both of which can produce IL13 and induce AHR.
The induction of IL33 synthesis in macrophages by asperamide Bactivated iNKT cells may help explain the capacity of A. fumigatus to induce AHR. IL33 is an innate cytokine that has been shown to potently cause AHR in the absence of adaptive immunity 33, 39, 41 . Notably, as only some glycolipids that activate iNKT cells induce AHR, the ability of asperamide B to induce IL33 production may be an important characteristic that distinguishes it from other glycolipids that cannot induce AHR. We hypothesize that alveolar macrophages take up only some iNKT cell-activating glycolipids, but these glycoli pids, when presented on CD1d to iNKT cells, result in the produc tion of IL33 by the macrophages, which then induces AHR. This IL33-ST2 axis may be crucial for the development of AHR and is dis tinct from the indirect iNKT cell-activation pathway, which involves IL12 and IFNγ 18, 27, 28 and clearance of infection. Thus, the specific glycolipid and APC with its associated cytokines together shape the response after iNKT cell activation and may help explain how iNKT cells selectively regulate distinct forms of immunity.
Moreover, because A. fumigatus is ubiquitous in the environment, respiratory exposure to A. fumigatus is common, and recognition of asperamide B by iNKT cells in some individuals may translate A. fumigatus exposure into respiratory disease. Although only 2-3% of individuals in the general population develop allergic sensitization to A. fumigatus (as determined by immediate skin test positivity) 42, 43 , approximately 28% of patients with asthma, including 45% of patients with severe asthma, develop A. fumigatus sensitization 9, 44 . The high rate of sensitization to A. fumigatus in severe chronic asthma may be due to the germination of spores in the lungs and exposure and sensitization to hyphae, which contain the asperamide B lipid. We therefore propose that the direct activation of iNKT cells by aspera mide B from A. fumigatus at the mucosal surface in the lungs may drive the development of allergic sensitization to Aspergillus and lead to AHR, particularly in patients with severe asthma 11, 45 .
Although iNKT cells may have evolved to respond rapidly to path ogenic microorganisms, their capacity to serve as an adjuvant for T H 2type immunity when activated has been previously suggested, for example, in response to environmental glycolipids from plant pollens 46 and in house dust 47 or cow's milk 48, 49 . Thus, in patients with allergic disease and asthma, it is possible that glycolipids from A. fumigatus, cypress tree pollen, cow's milk and Sphingomonas spe cies (which are often found in the lungs of patients with poorly con trolled asthma 50 ) all activate iNKT cells, which then provide potent adjuvant activity to enhance allergic, T H 2 cell-adaptive sensitization to the accompanying proteins. The environment may thus be replete with such iNKT cell-activating compounds that are recognized and sensed by iNKT cells and that may enhance allergic sensitization 51 . As such, iNKT cells, which may be increased in number in the mucosa of allergyprone children 52 , may have a crucial role in allergy and aller gic asthma. This idea is also consistent with the observation that most protein allergens have lipidbinding activity 53, 54 , which may allow glycolipids that activate iNKT cells to associate with these clinically important protein allergens, facilitating T H 2 cell sensitization.
METHODS
Methods and any associated references are available in the online version of the paper.
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